News
Click here to subscribe to our news updates
Select year:
2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016
Click here for announcements regarding managers transactions.
Click here for news in Danish.
September 05, 2025 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseAugust 26, 2025 | Company Announcements
Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira August 26, 2025 | Company Announcements
Publication of offer document in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira and lowering of minimum acceptance condition to 75%August 22, 2025 | Company Announcements
Bavarian Nordic Announces First Half 2025 ResultsJuly 31, 2025 | Company Announcements
Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial GuidanceJuly 28, 2025 | Company Announcements
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian NordicJuly 24, 2025 | Company Announcements
Rumours of a Potential Takeover Offer for Bavarian Nordic A/SJuly 09, 2025 | Company Announcements
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European CountryJune 18, 2025 | Company Announcements
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 MillionMay 09, 2025 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2025May 06, 2025 | Company Announcements
Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox VaccinesApril 16, 2025 | Company Announcements
Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)April 09, 2025 | Company Announcements
Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/SMarch 31, 2025 | Company Announcements
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine March 12, 2025 | Company Announcements
Bavarian Nordic A/S – Notice Convening Annual General Meeting March 05, 2025 | Company Announcements
Bavarian Nordic Publishes Annual Report 2024February 28, 2025 | Company Announcements
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and OlderFebruary 14, 2025 | Company Announcements
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and OlderFebruary 03, 2025 | Company Announcements
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025January 31, 2025 | Company Announcements
Bavarian Nordic – Completion of Share Buy-Back ProgramJanuary 31, 2025 | Company Announcements
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and OlderJanuary 27, 2025 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program January 20, 2025 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program January 09, 2025 | Company Announcements
Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 MillionDecember 13, 2024 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic